Advancing health through genetics and precision medicine

41st Annual J.P. Morgan Healthcare Conference
January 9, 2023

Paul J. Diaz
President and CEO
Myriad Genetics
Forward-looking statements and non-GAAP financial measures

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company.

These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company’s annual report on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company’s projections or forward-looking statements. Market opportunity figures used in this presentation are estimates based on Company and third-party research.

In this presentation, the Company’s financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company’s core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company’s business. A reconciliation of the GAAP to non-GAAP financial results is provided under the investor section of Myriad’s corporate website at www.myriad.com.
Revealing the power of genetic science – for everyone

Mission
We advance health and well-being for all, empowering every individual by revealing the answers inside each of us.

Vision
As a leader in genetic testing and precision medicine, we provide insights that help people take control of their health, and enable healthcare providers to better detect, treat and prevent disease.

Health. Illuminated.

Moving from transformation to innovation and growth
Myriad Genetics at a glance

- **A leader in genetic testing**
  Established franchises in hereditary cancer, pharmacogenomics, and prenatal testing

- **30+ years of scientific and commercial achievements**
  1,000+ scientific publications and counting

- **60,000+ active ordering physicians**
  73 net promoter score

- **2,600 employees**

- **10%+ annual revenue growth target by ’24**
  Commercial execution driving volume growth; price stability

- Market-leading gross margins; healthy balance sheet

- **Innovation in ’23 and beyond**
  On track to launch multiple differentiated tests in prenatal and oncology
Context, opportunities and challenges

Healthcare is quickly evolving to be more patient-centered and value-based.

Genetic insights and precision medicine can play an important role in advancing care, improving access and reducing costs.

Myriad Genetics is evolving to play a bigger role.

Molecular diagnostics, biotech, and biopharma industries have experienced significant disruption and growing pains over the last year creating organic and inorganic opportunities for Myriad Genetics.
### A diversified growth story driven by three focused businesses

<table>
<thead>
<tr>
<th>Business</th>
<th>Market Size*</th>
<th>Operating Results</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mental Health</td>
<td>$5 Billion</td>
<td>Q3 ’22 volume: ~97K</td>
<td>Q3 ’22 revenue: $33.0M</td>
</tr>
<tr>
<td>Women’s Health</td>
<td>$4 Billion</td>
<td>Q3 ’22 volume: ~112K</td>
<td>Q3 ’22 revenue: $54.3M</td>
</tr>
<tr>
<td>Oncology</td>
<td>$24 Billion</td>
<td>Q3 ’22 volume: ~47K</td>
<td>Q3 ’22 revenue: $69.2M</td>
</tr>
</tbody>
</table>

* Based upon company and third party estimates and industry research; Oncology market size incorporates estimates for MRD market.
Mental Health: GeneSight® momentum continues

2022 achievements

+40% YoY volume growth¹

+3K New providers added every quarter in 2022¹

1.6M Website visitors per year²

Next two years: Key growth drivers

Growing awareness of pharmacogenomic opportunities for mental health treatment; Driving physician adoption/utilization

Expanding reimbursement coverage

Potential expansion of indications

>95% of tests placed through online portal

25% of orders by a clinician for at-home testing

1. YTD as of September 30, 2022
2. Annualized based on 809K visitors from January to June 2022
Effective and scalable commercial sales and marketing model

GeneSight®
Addressable Market

Depression medication
Anxiety medication
ADHD medication

5M
Addressable patients

1.6M
Unique web users

250K+
Leads

300K+
Orders

Actively applying proven model to Women’s Health

Data shown represents annualized 1H22 activity in the United States
Women’s Health: Innovation to drive growth

2022 achievements

- +7% Number of ordering providers
- +4% HCT test volume growth YoY
- +18% per pre-natal test ASP improvement

Next two years: Key growth drivers

- Deploying new sales and marketing model in Q1 ’23
- Improving access and ease of use through unified ordering portal

FirstGene™
Comprehensive Prenatal Screen

- New 4-in-1 prenatal offering for NIPS, carrier screen, fetal recessive status and feto-maternal blood compatibility
- Positive recent guideline and recommendation updates
- Gateway Genomics cross-selling synergies

---

1. Based on Q3 ’22 vs. Q1 ’22
2. Based on Q3 ’22
3. Year-over-year change as of Q3 ’22
Product and channel expansion

- Expands Myriad’s Women’s Health portfolio with SneakPeek early gender DNA test, revealing babies’ fetal sex at 6 weeks from home with 99% accuracy – earliest method yet
- Strengthens Myriad as trusted lab for prenatal and hereditary cancer testing
- Extends market reach via direct-to-consumer website, online channel partners, and 1,850 clinicians
- SneakPeek revenue grew at 20%+ CAGR over the last three years

#1 selling DNA test on Amazon

Top-searched fetal sex test on Google – 9K+ 4.5-star reviews

4M annual website visitors

SneakPeek Snap™ blood collection device – easy, painless

Excellent net promoter score: 76

750,000 SneakPeek tests to date
Expanding breadth of portfolio addressing real-world community needs

Planned Product Expansion:
- MyRisk™: High Risk Screening
- MyRisk RiskScore®: Surgical Decisions
- Prolaris®: Prognostic Testing
- MyChoice CDx: Treatment Selection & Clinical Trials
- Precise Tumor: Measurable Residual Disease
- BRACAnalysis CDx+: Monitoring Recurrence
- Precise Liquid: Therapeutic Selection
- Precise MRD: Minimal Residual Disease Monitoring

Next two years: Key growth drivers
- New commercial team leadership
  - Michael Lyons, general manager
- Precise Oncology Solutions ramp
- Prolaris improved coverage
- Precise MRD for Pharma (Mid ‘23)
- Clinical utilization (‘24)
Enhancing our commercial capabilities to drive future growth

Attracting top talent in key strategic areas
- Glenn Farrell, CHIEF MARKETING OFFICER
- Marc Leighton, SVP OF PRODUCT MANAGEMENT
- Michael Lyons, GENERAL MANAGER OF ONCOLOGY
- John Oberg, SVP OF BUSINESS DEVELOPMENT
- Lisa Olson-Coombe, VP OF LAB TRANSFORMATION

Deploying new commercial sales and marketing capabilities
- Deploy proven GeneSight® commercial model in Women’s Health and Oncology
- Adapt our go-to-market model to large health systems by building enterprise-wide relationships

Strengthening engagement and product messaging
- Narrowed competitive gap on perception among providers and patients
- Engagement with Genetic Counselor community

Extending value beyond product quality to lead on the experience and accessibility
- Solved for price transparency and patient affordability
- Partnered with EPIC on EMR
- Roll out unified ordering portal and ongoing improvements to Myriad Complete™
# Active pipeline to serve patients and providers

**Women’s Health**

**FirstGene™**
4-in-1 prenatal screening

*What is It?*
Single integrated assay for NIPS, carrier screen, fetal recessive status and feto-maternal blood compatibility on a single blood draw on one person

*Key advantages*
- Fewer inconclusive fetal recessive results; faster turnaround time; 3x lower cost of goods
- Established reimbursement path

*Target launch – Q3 '23*

---

**Oncology**

**Precise™ Tumor**
Robust tumor profiling & therapy selection

*What is It?*
Pan-cancer comprehensive genomic profiling test using Illumina TruSight Oncology 500; may serve as first-line offering

*Key Advantages*
- Panel size ~2x size (500 genes) of lead competitor; uses both DNA/RNA; ease of use as part of Precise Oncology Solutions
- Established reimbursement path

*Commercialized – 2022*

**Precise™ Liquid**
Robust tumor profiling & therapy selection

*What is It?*
Comprehensive genomic profiling test; may serve as first-line offering or as reflex if solid tumor is insufficient

*Key Advantages*
- Panel size ~2x size (500 genes) of lead competitor; uses both DNA/RNA; ease of use as part of Precise Oncology Solutions
- Established reimbursement path

*Target launch – 2H '23*

**Precise™ MRD**
Minimal residual disease monitoring

*What is It?*
Monitoring test based on whole genome sequencing to deeply interrogate tumor, detect recurrence earlier and help guide treatment decisions

*Key Advantages*
- Targets 10x variants
- Known path to reimbursement

*Target launch – RUO* mid-23

---

*Research Use Only*
Execution plan supported by significant investment and top talent

<table>
<thead>
<tr>
<th>NovaSeq Transitions</th>
<th>FirstGene™</th>
<th>New Facility Construction</th>
<th>Shift Operations to New Facilities</th>
<th>Advanced Automation</th>
<th>MRD</th>
<th>Liquid Biopsy</th>
<th>Whole Exome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prenatal products shift to advanced sequencing</td>
<td>New Prenatal combined test offering</td>
<td>South San Francisco innovation campus construction</td>
<td>Transition Innovation operations to new South San Francisco facility</td>
<td>Design and build first phases of automation</td>
<td>Measurable Residual Disease detection offering</td>
<td>Liquid Tumor profiling</td>
<td>Phased approach RUO → LDT → CDx</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Salt Lake City production lab campus construction</td>
<td>Transition Prenatal production to Salt Lake City</td>
<td>Early phase Prenatal lab automation</td>
<td>RUO</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Transition Salt Lake City Research Park products to new campus</td>
<td>Fully automate Prenatal labs</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*$80M* investment in modern labs

*$12M* annual savings starting in 2025

>85% of investment is estimated to be capitalizable expense
Advancing health through genetics and precision medicine

Innovation and upcoming product launches

Dale Muzzey, Ph.D.
Chief Scientific Officer
Myriad Genetics
Entering an exciting period of commercialized innovation

FirstGene™
4-in-1 prenatal screening

What is it?
Single integrated assay for NIPS, carrier screen, fetal recessive status and fetomaternal blood compatibility on a single blood draw on one person.

Precise™ Liquid
Robust tumor profiling & therapy selection

What is it?
Comprehensive genomic profiling test; may serve as first-line offering or as reflex if solid tumor is insufficient.

Precise™ MRD
Minimal residual disease monitoring

What is it?
Monitoring test based on whole genome sequencing to deeply interrogate tumor and detect recurrence earlier and help guide treatment decisions.
FirstGene™
4-in-1 Prenatal Screen

Advantages relative to alternative approaches

3X the number of genes\(^1\)
2X faster turnaround time for fetal affected status\(^2\)
3X fewer samples with inconclusive fetal recessive results due to low fetal fraction\(^3\)
3X lower COGS\(^4\)

1 Expected panel size of FirstGene compared to UnityScreen panel
2 FirstGene will perform fetal recessive testing in a single assay, rather than two sequential assays
3 Estimate based on comparison between FirstGene internal data and Westin et al., 2022, American Journal of Hematology
4 Estimate based on internal analysis of running FirstGene versus separately running carrier screening, aneuploidy NIPS, and single-gene NIPS
4-in-1 Prenatal Screen

FirstGene™
4-in-1 Prenatal Screen

NIPS for common aneuploidies
Carrier screening for common conditions
Fetal recessive status (affected, carrier, normal)
Feto-maternal blood compatibility

Single blood draw on one person

No testing of father required
FirstGene™ powered by AMPLIFY™ technology

FirstGene™ estimated to have 3X fewer samples with inconclusive fetal recessive results due to low fetal fraction*

Take the AMPLIFY technology from Prequel and port to FirstGene for superior fetal fraction

*Based on comparison between FirstGene internal data and Westin et al., 2022, American Journal of Hematology
Before getting to MRD...

an important update to our Comprehensive Genomic Profiling offering

• Both solid and liquid assays test >500 genes; solid test includes RNA analysis to detect fusions

• Precise Liquid can serve as stand-alone product for certain indications and reflex for cases where solid tumor sample is insufficient or low-quality

• Underlying panel utilized in >75 peer-reviewed manuscripts, including clinical validation studies
Precise™ MRD
Minimal Residual Disease Monitoring

Advantages¹ relative to alternative approaches

30X
More sites interrogated via Precise MRD

>10X
Lower tumor-fraction detection threshold

100X
More of the cancer genome explored

Expect to announce pilot study soon with leading cancer center

¹ Figures are based on the estimated performance of Precise MRD compared to a competitor MRD test.
Serial MRD monitoring can detect recurrence prior to imaging

<table>
<thead>
<tr>
<th></th>
<th>Pre-surgery</th>
<th>Post-surgery</th>
<th>3mo</th>
<th>6mo</th>
<th>9mo</th>
<th>12mo</th>
<th>15mo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imaging</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MRD</td>
<td>N/A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

MRD testing detects tumor recurrence earlier than imaging.

MRD measures tumor-derived cell-free DNA in blood plasma via sequencing.

Two main flavors of MRD: tumor-informed and tumor-naïve
- Tumor-informed optimized for sensitive and specific detection of patient’s particular tumor
- Tumor-naïve confers speed advantage only for earliest time point

Myriad’s Precise™ MRD is a high-definition MRD assay, informed by tumor-specific variants across the whole genome.
High-definition MRD: differentiation built upon existing competencies

- **Tumor + normal sample prep and sequencing**
- **Bioinformatic identification of somatic variants**
- **cfDNA isolation and targeted sequencing**
- **Detect presence or absence of tumor cfDNA**

<table>
<thead>
<tr>
<th>Comparable Myriad test</th>
<th>MyChoice®CDx</th>
<th>FirstGene™</th>
</tr>
</thead>
</table>

- **Somatic variant identification**
  - **Competitor**
    - Exome
  - **Whole genome**

- **Number of sites interrogated in plasma sample**
  - **Competitor**
    - 16 sites
  - **≥500 sites**

- **Earlier detection of recurrence**
- **Higher sensitivity in more tumors**
- **More sites**
Excellent performance of high-definition MRD across tumor types

- >300 sites provide very high confidence at 0.01% tumor fraction
- Approach works consistently across tumor types
- Efforts underway to lower detection threshold to call at 0.0001%

Precise™ MRD has >99% sensitivity at 0.01% tumor fraction

Colorectal

Endometrial

Ovarian

Detection limit of competitor’s assay

Tumor fraction (%)
High-definition MRD: key milestones

### 2023

- **Launch Research-Use-Only (RUO) test in mid-'23**
  Run entirely in-house; mostly automated

- **Submit analytical validation for peer review**
  Conference abstracts and journal article

- **Partner on retrospective clinical validation**
  Work with leading cancer centers eager to use HD-MRD

- **Begin prospective clinical validity study**
  Working with Intermountain Healthcare; other institutions onboarding

- **Apply HD-MRD for biopharma partners**
  Gain investigational-device exemption status for use in prospective trials

### 2024

- **Launch Lab Developed Test (LDT)**
  Focus on BRCA-related cancers

- **Publish clinical validity studies**
  Retrospective longitudinal cohorts; one per indication

- **Submit for reimbursement to CMS**
  Show non-inferiority to currently covered tumor-informed tests

- **Commence clinical-utility study**
  Focus on provider utilization and patient outcomes

- **Scale laboratory operations**
  Low-touch, high-capacity, and high-quality with low COGS

- **Apply HD-MRD for biopharma partners**
  Gain investigational-device exemption status for use in prospective trials
Advancing health through genetics and precision medicine

Financial highlights and closing comments

Paul J. Diaz
President and CEO
Myriad Genetics
Financial highlights:
Accelerating growth through prudent investment strategy

Total revenue

YTD Q3 ‘22
$500 Million

Adjusted gross margin

2020  2021  2022

27%

71%

Strong balance sheet with minimal cash burn
Continue to invest in high ROI opportunities within core areas
Committed to enhancing our lab infrastructure - Labs of the Future strategy
Disciplined capital deployment

1 YTD as of September 30; revenue excludes divested businesses
2 YTD as of September 30, 2022
Our path to 10%+ annual revenue growth target by 2024

Convey Myriad’s competitive differentiation and our commitment to being a **reliable genetic testing partner** to patients and providers

Extend **commercial sales and marketing model from Mental Health to Women’s Health and Oncology** to reach a broader set of physicians and raise awareness with patients who should be tested

Continue to **make it easier to partner with us**: ease of ordering, EHR integration, data sharing for clinical care, scientific research and at home testing

Successfully launch **FirstGene™ and Precise™ Liquid** in 2023 and **Precise™ MRD** for Pharma use in 2023
Investment considerations: Myriad strengths and strategic advantages

Leader in genetic testing and precision medicine

- Transformation and growth strategy on track
- Broad and growing commercial capabilities with 60K+ healthcare providers ordering Myriad products across Women’s Health, Oncology and Mental Health
- Commercial platform with market-leading breadth of payer relationships and revenue cycle management capabilities
- Trusted, differentiated healthcare partner with specialized expertise